Science 37 Named Best in Class for Telehealth Innovation at UCSF Health Hub Digital Health Awards 2022
November 15 2022 - 5:00PM
Science 37 Holdings, Inc. (Nasdaq: SNCE), the industry-leading
Metasite™, was named as winner in the Telehealth Innovation
category at the University of California San Francisco (UCSF)
Health Hub Digital Health Awards, at the 2022 HLTH conference.
Science 37’s tech-enabled virtual site, known as a Metasite,
leverages telemedicine to execute tech-enabled clinical trials that
are faster, more inclusive, and patient-centric. Built on a unified
platform, telehealth allows investigators to oversee the
administration of treatments or procedures by mobile
nurses—regardless of the patient’s location. The telemedicine
functionality supports seamless data capture, ensuring safety and
high-quality data, throughout the clinical trial.
“The Science 37 unified platform continues to be acknowledged as
best-in-class, supporting patients and sponsors, globally,” said
Troy Bryenton, Chief Technology Officer of Science 37. “The
security, privacy, and ease of use of our platform are of utmost
importance to users in the clinical trial industry, as we continue
to enable access for patients anywhere.”
Unlike many of the point solutions that enable components of
decentralization, the Science 37 unified platform combines all the
necessary technology to enable a virtual site, including eConsent,
eCOA/ eSource, and wearable/ device integration. This end-to-end
SaaS (software as a service) platform coordinates clinical research
across all settings of care, delivering a streamlined experience
for participants, investigators, site staff, and community
providers—regardless of location. The Science 37 unified platform
orchestrates clinical trial workflows, enables evidence generation,
and data harmonization to the highest degree of accuracy,
consistency, and reliability.
About Science 37Science 37, Inc.’s (Nasdaq:
SNCE) mission is to accelerate clinical research by enabling
universal access for patients. In 2014, we pioneered decentralized
clinical trials, and we continue to lead, delivering faster, more
inclusive, patient-centric trials, by removing barriers to access
through a tech-enabled virtual site. The Science 37 Metasite™
leverages a unified set of people, processes, and technology,
delivering greater consistency and regulatory-quality data. With
the most medical and operational experience across therapeutic
areas, Science 37 has enabled up to 21x faster enrollment, 28%
better retention, and 3x more diversity vs. the traditional site.
To learn more, visit www.science37.com, or email
science37@science37.com.
Cautionary
Note Regarding Forward-Looking StatementsThis press
release contains certain forward-looking statements within the
meaning of the federal securities laws, including statements
regarding the products offered by Science 37, its sales pipeline
and the markets in which it operates. These forward-looking
statements generally are identified by the words “believe,”
“project,” “expect,” “anticipate,” “estimate,” “intend,”
“strategy,” “future,” “opportunity,” “plan,” “may,” “should,”
“will,” “would,” “will be,” “will continue,” “will likely result”
and similar expressions. Forward-looking statements are
predictions, projections and other statements about future events
that are based on current expectations and assumptions and, as a
result, are subject to risks and uncertainties. Many factors could
cause actual future events to differ materially from the
forward-looking statements in this press release, including but not
limited to: (i) the ability to maintain the listing of Science 37’s
securities on Nasdaq, (ii) volatility in the price of Science 37’s
securities due to a variety of factors, including changes in the
competitive and highly regulated industries in which Science 37
operates, variations in performance across competitors, changes in
laws and regulations affecting Science 37’s business and changes in
its capital structure, (iii) the ability to implement business
plans, forecasts, and other expectations, and to identify and
realize additional opportunities, (iv) the risk that Science 37 may
never achieve or sustain profitability, (v) the risk that Science
37 will need to raise additional capital to execute its business
plan, which may not be available on acceptable terms or at all,
(vi) failure to realize anticipated cost savings, and (vii) the
potential adverse effects of the ongoing global COVID-19 pandemic.
The foregoing list of factors is not exhaustive. You should
carefully consider the foregoing factors and the other risks and
uncertainties described in the “Risk Factors” section of our Annual
Report on Form 10-K for the fiscal year ended December 31, 2021
filed with the U.S. Securities and Exchange Commission (the “SEC”)
on March 22, 2022 and in our other documents filed by Science 37
from time to time with the SEC. These filings identify and address
other important risks and uncertainties that could cause actual
events and results to differ materially from those contained in the
forward-looking statements. Forward-looking statements speak only
as of the date they are made. Readers are cautioned not to put
undue reliance on forward-looking statements, and Science 37
assumes no obligation and does not intend to update or revise these
forward-looking statements, whether as a result of new information,
future events, or otherwise, except as required by law. Science 37
does not give any assurance that Science 37 will achieve its
expectations.
MEDIA INQUIRIES:Grazia MohrenScience
37PR@science37.com
INVESTOR RELATIONS:Steve HalperLifeSci
AdvisorsInvestors@science37.com
Science 37 (NASDAQ:SNCE)
Historical Stock Chart
From Sep 2024 to Oct 2024
Science 37 (NASDAQ:SNCE)
Historical Stock Chart
From Oct 2023 to Oct 2024